180 Life Sciences Corp

NASDAQ:ATNF  
0.88
+0.03 (+3.75%)
Products, Regulatory, Other Pre-Announcement

180 Life Sciences Provides Update On Correspondence Received From U.K. And U.S. Regulatory Authorities On Pathway For A Therapy That Could Prevent Progression Of Early-Stage Dupuytren's Disease

Published: 06/14/2022 21:09 GMT
180 Life Sciences Corp (ATNF) - 180 Life Sciences Provides Update on Correspondence Received From Uk and U.S. Regulatory Authorities on Pathway for a Therapy That Could Prevent Progression of Early-stage Dupuytren’s Disease.
180 Life Sciences Corp - Plans to Request a Pind Meeting.
180 Life Sciences Corp - FDA Recommended Considering a Pre-investigational New Drug (pind) Meeting Request to Receive Further Regulatory Guidance.